From Analysis:
AD Master Plan preregistration: GFAP
GFAP-positive reactive astrocytes mediate regional vulnerability through dysfunction of metabolic support, driving AD progression in affected regions
Claims from this analysis should be evaluated across GFAP, AD, tau, amyloid; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.
No AI visual card yet
Theorist position for analysis AD-MASTER-PLAN-GFAP-20260428030756: AD Master Plan preregistration: GFAP
Context: Preregistered claim: GFAP-positive reactive astrocytes mediate regional vulnerability through dysfunction of metabolic support, driving AD progression in affected regions
Primary claim: GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan p
Skeptic critique for analysis AD-MASTER-PLAN-GFAP-20260428030756: AD Master Plan preregistration: GFAP
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: GFAP is a state marker more than a specific intervention point, and reactive astrocytes can be protective or harmful.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across GFA
Domain expert assessment for analysis AD-MASTER-PLAN-GFAP-20260428030756: AD Master Plan preregistration: GFAP
The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.
Feasibility is
{
"ranked_hypotheses": [
{
"title": "GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD requires proximal validation",
"description": "The debate supports carrying forward GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD only if a proximal endpoint changes before the late outcome. The decisive validation path is: resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems.",
"target_gene": "GFAP",
"dim
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for AD.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
None | 2026-04-27 | prereg
No comments yet. Be the first to comment!